Healthcare Press

Clinical Trial for Gene Editing Treatment Paused Due to Laboratory Abnormalities

  • 📰 Medscape
  • ⏱ Reading Time:
  • 10 sec. here
  • 7 min. at publisher
  • 📊 Quality Score:
  • News: 24%
  • Publisher: 55%

Health News

Gene Editing,LDL Cholesterol,Clinical Trial

The clinical trial for a gene editing treatment to lower LDL cholesterol levels has been paused due to laboratory abnormalities in one participant. The safety of patients in the clinical trials is a top priority.

The clinical trial for a gene editing treatment to lower LDL cholesterol levels has been paused due to laboratory abnormalities in one participant. The treatment, called VERVE-101, uses CRISPR-based gene editing to permanently turn off a gene in the liver.

However, certain asymptomatic laboratory abnormalities were observed at potentially therapeutic dose levels of the treatment. The safety of patients in the clinical trials is a top priority.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 386. in HEALTH

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Baylor Scott & White clinical trial brings new hope to Arlington man, who's now cancer free'We celebrate our wins,' said Kenny Keown. 'I've been blessed through this process,' he said of a Baylor Scott & White Health clinical trial.
Source: wfaa - 🏆 543. / 51 Read more »